|
Main page Cancer blog Health blog Articles Resources
Finding new targets for gastric cancer
A research team led by Dr. Liang Wang from China investigated whether bone marrow-derived DCs (BM-DCs) pulsed with tumor lysates induce immunity against gastric cancer. Their results will be published on December 14, 2008 in the World Journal of Gastroenterology In this study, c-kit+ hematopoietic progenitor cells were magnetically isolated with a MiniMACS separator from BALB/c mice bone marrow cells. These cells were cultured with cytokines GM-CSF, IL-4, and TNF-alpha to induce their maturation. They were analysed by morphological observation, phenotype analysis, and mixed lymphocyte reaction (MLR). BM-DCs were pulsed with tumor cell lysate obtained by rapid freezing and thawing at a 1:3 DC:tumor cell ratio. Finally, CTL activity and interferon-gamma secretion was reviewed ex vivo. They observed that c-kit+ hematopoietic progenitor cells from mice bone marrow cells cultured with cytokines for 8 d showed the character of typical mature DCs. However, immature DCs cultured with cytokines for 5 d did not have typical DCs phenotypic markers and could not stimulate allogeneic T cells. Ex vivo primed T cells with SGC-7901 tumor cell lysate-pulsed (TP) DCs were able to induce effective CTL activity against SGC-7901 tumor cells (E:T = 100:1, 69.55% 6.05% specific lysis), but not B16 tumor cells, and produced higher levels of IFN-gamma when stimulated with SGC-7901 tumor cells but not when stimulated with B16 tumor cells (1575.31. 60.25 pg/mL in SGC-7901 group vs 164.11 18.52 pg/mL in B16 group, P < 0.01). These results indicated that BM-derived DCs pulsed with tumor lysates can induce anti-tumor immunity specific to gastric cancer ex vivo. Posted by: Jessica Source |
|